OVOL1

OVOL1 is a C2H2 zinc-finger transcriptional repressor that enforces epithelial identity and terminal differentiation by directly binding promoters of proliferation- and mesenchymal-program genes to suppress their transcription (PMID:16636146, PMID:31934116). During the proliferation-to-differentiation switch in epidermal progenitors it directly represses c-Myc to drive growth arrest (PMID:16636146), and it represses Id2 in spermatocytes where its loss blocks meiotic progression (PMID:15716349); repression is implemented in part through an N-terminal SNAG domain that recruits HDAC activity, a mechanism OVOL1 also uses to auto-repress its own promoter by competing with the activator c-Myb (PMID:17311813). OVOL1 sits within a self-limiting epithelial regulatory network, directly repressing OVOL2 (PMID:17049212, PMID:28339425) and the EMT driver ZEB1 to promote mesenchymal-to-epithelial transition and curb cancer cell migration and invasion (PMID:24124593, PMID:31934116), and repressing the Hippo effector YAP through an HDAC-dependent mechanism to suppress squamous carcinoma stemness and metastasis (PMID:42217551). In skin, OVOL1 is a conserved direct transcriptional target of AhR signaling and acts downstream of AhR to maintain the epidermal barrier and restrain inflammation, repressing the neutrophil chemokine Cxcl1 and engaging Id1 as a key barrier-maintaining effector; its keratinocyte-specific loss aggravates psoriasis- and atopic-dermatitis-like inflammation (PMID:28703805, PMID:34461129, PMID:39939818). Beyond transcriptional repression, OVOL1 also acts at the protein level, binding SMAD7 to block its ubiquitination and thereby attenuating TGF-β/SMAD signaling within a BMP-driven positive feedback loop (PMID:35484112). OVOL1 activity is itself constrained by signals that block its nuclear translocation or trigger its degradation, including IL-4 and IL-13/calpain-14, the latter coupling cytokine signaling to loss of OVOL1-dependent SPINK7 expression and barrier impairment (PMID:28703805, PMID:42048165).

1. 2005 High

   Established OVOL1 as a transcriptional repressor with a defined developmental role by showing it silences Id2 to permit meiotic progression, framing the protein as a gatekeeper of cell-state transitions.

   Evidence Ovol1 knockout mouse, transcriptional profiling and reporter assays in pachytene spermatocytes

   PMID:15716349

   Open questions at the time

   • Did not define the DNA-binding sequence or repression domain
   • Mechanism of cyclin B1 mislocalization downstream of Id2 left open
2. 2006 High

   Showed OVOL1 directly represses c-Myc and Ovol2 promoters, linking it mechanistically to the proliferation-to-differentiation switch in epidermal progenitors and revealing a repressive regulatory cascade among OVOL family members.

   Evidence ChIP, reporter assays with DNA-binding mutants, Ovol1 knockout keratinocyte proliferation assays

   PMID:16636146 PMID:17049212

   Open questions at the time

   • Did not identify the co-repressor machinery recruited to these promoters
   • Direct vs indirect effects on broader differentiation program not fully separated
3. 2007 High

   Resolved the repression mechanism by identifying the N-terminal SNAG domain as an HDAC-recruiting module and demonstrating auto-repression via competition with the activator c-Myb, explaining how OVOL1 levels are self-limited.

   Evidence ChIP for histone acetylation and c-Myb/Ovol1 occupancy, domain mutagenesis, reporter assays

   PMID:17311813

   Open questions at the time

   • Specific HDAC isoform not identified
   • Whether SNAG-HDAC recruitment operates at all OVOL1 target genes not tested
4. 2009 Medium

   Placed OVOL1 within an upstream regulatory hierarchy by showing NGN3 and NEUROD1 repress its transcription in an E-box-dependent manner, extending OVOL1 regulation beyond epithelia.

   Evidence ChIP-cloning and transactivation reporter assays in rodent pancreas

   PMID:19882138

   Open questions at the time

   • Functional consequence of OVOL1 repression in pancreas not established
   • Single lab, model-organism context
5. 2013 Medium

   Connected OVOL1 to cancer cell-state control by demonstrating it drives mesenchymal-to-epithelial transition through a feedback loop with ZEB1 and induction of ESRP1, suppressing metastatic potential.

   Evidence Overexpression in cancer cells, mouse prostate tumor models, expression analysis across 917 cell lines

   PMID:24124593

   Open questions at the time

   • Molecular mechanism of ZEB1 regulation not resolved at this stage
   • Direct vs indirect ESRP1 induction unclear
6. 2017 High

   Defined the AhR→OVOL1→filaggrin axis in keratinocytes and showed IL-4 blocks OVOL1 nuclear translocation, establishing OVOL1 as a cytokine-controlled barrier regulator and an effector of skin immune homeostasis.

   Evidence Gain/loss-of-function in NHEKs, AHR ligand treatment, nuclear translocation assays; siRNA epistasis in A431 cells

   PMID:28339425 PMID:28703805

   Open questions at the time

   • Whether FLG regulation is direct not shown
   • Mechanism by which IL-4 blocks nuclear import not defined
7. 2019 Medium

   Confirmed direct ZEB1 promoter repression by OVOL1 and placed OVOL1 downstream of a Jarid1b-AKT axis, integrating chromatin and signaling inputs into epithelial differentiation control.

   Evidence ChIP and reporter assays with ZEB1 rescue in OSCC; ChIP for H3K4me3 and PI3K-AKT inhibitors in epidermal grafts

   PMID:31152465 PMID:31934116

   Open questions at the time

   • How AKT increases OVOL1 expression not mechanistically defined
   • Single-lab findings
8. 2021 High

   Demonstrated in vivo that epidermal OVOL1 maintains barrier integrity and restrains psoriasis-like inflammation by directly repressing the neutrophil chemokine Cxcl1, linking OVOL1 loss to a defined inflammatory phenotype.

   Evidence Skin-specific Ovol1 knockout, imiquimod psoriasis model, ChIP, bulk RNA-seq

   PMID:34461129

   Open questions at the time

   • Relative contribution of Cxcl1 vs other targets to phenotype not quantified
   • IL-33 only weakly direct
9. 2022 High

   Revealed a non-transcriptional mechanism whereby OVOL1 stabilizes SMAD7 by preventing its ubiquitination, thereby attenuating TGF-β receptor signaling within a BMP-driven positive feedback loop.

   Evidence Co-immunoprecipitation, ubiquitination assays, overexpression/knockdown with migration/invasion assays in breast cancer cells

   PMID:35484112

   Open questions at the time

   • Co-IP without reciprocal endogenous validation
   • How OVOL1 shields SMAD7 from the E3 ligase not defined
10. 2025 High

    Used genome-wide ChIP-seq to define OVOL1's direct target landscape and established it as a conserved AhR target essential for AhR's barrier-promoting function, identifying Id1 as a key effector.

    Evidence Genome-wide ChIP-seq, keratinocyte-specific knockout, in vivo AD model, single-cell analyses

    PMID:39939818

    Open questions at the time

    • Functional role of most genome-wide targets not individually validated
    • Mechanism by which Id1 maintains barrier not detailed
11. 2026 Medium

    Extended OVOL1's repressive program to the Hippo effector YAP and to SPINK7 activation, and showed IL-13/calpain-14 degrades OVOL1 to impair the esophageal barrier, unifying its tumor-suppressive and barrier-maintaining roles under cytokine control.

    Evidence ChIP/reporter/Co-IP in ESCC; SPINK7 reporter, nuclear translocation, calpain-14 inhibition in esophageal biopsies

    PMID:42048165 PMID:42217551

    Open questions at the time

    • SPINK7 regulation shown as activation, contrasting OVOL1's repressor role, mechanism unresolved
    • Single-lab findings

• How OVOL1 switches between transcriptional repression of most targets and apparent activation of SPINK7, and what determines its context-dependent tumor-suppressive versus tumor-promoting roles, remains unresolved.
• No unified model for repressor vs activator behavior
• Direct transcriptional control of metabolic targets such as APOE not established by ChIP
• Structural basis of DNA recognition and co-factor switching unknown